13/01/2023at 15:45

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup

Potential blockbuster submitted by Novo Nordisk for European approval

The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Photo: Viatris/PR.

Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

For subscribers

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Photo: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Spokesperson: Laid-off Leo employees have leg-up in job hunt at Novo and Lundbeck

Dismissed Leo Pharma workers get to skip the line when looking for jobs at Novo Nordisk and Lundbeck via a new job tunnel – and Bavarian Nordic would like to snatch a few people up, too.

For subscribers

Pharma & biotech

Analyst: Priority review for Lundbeck-Otsuka Alzheimer's agitation drug signals unmet need

A four-month reduction to case processing is positive and could boost Lundbeck stock, says an analyst, noting that the regulatory win is also recognition of an unmet medical need.

For subscribers

Johan Luthman, executive vice president for research and development at Lundbeck | Foto: Lundbeck / Pr

Pharma & biotech

Lundbeck: Alzheimer's agitation drug can make a real difference

Head of R&D Johan Luthman is pleased that Lundbeck’s Alzheimer’s agitation treatment candidate has gotten the FDA’s priority designation – ”agitation is one of the most troublesome aspects of the disease.”

For subscribers

Latest news

See all

Jobs

Regulatory Affairs Professional

See all jobs

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Top news from MedWatch this week

Monday

Tuesday

Wednesday

Thursday

Friday

Sign up for our newsletter

Front page now

Potential blockbuster submitted by Novo Nordisk for European approval

Novo Nordisk sues Viatris over copycat Wegovy

Novartis beats Kesimpta sales expectations in Q4

Analyst: Strong Novo Nordisk outlook should satisfy investors

Studies of Wegovy in higher-than-approved doses begin

Rare Disease business comes in slightly below expectations for Novo Nordisk

Further reading

Spokesperson: Laid-off Leo employees have leg-up in job hunt at Novo and Lundbeck

Analyst: Priority review for Lundbeck-Otsuka Alzheimer's agitation drug signals unmet need

Lundbeck: Alzheimer's agitation drug can make a real difference

Latest news

Jobs

Jobs